ALFA Finder| Management target | EBITDA Year 2 |
|---|
| Revenue growth | 9% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin expanded 241 bps YoY to 23.2%. |
| Demand visibility | Strong, driven by higher MR productivity and key brand strength. |
| Management confidence | High; citing sustained traction and disciplined capital allocation. |
Growth
Q1FY27 Revenue reached ₹822 Mn (+8.8% YoY); Operating EBITDA rose to ₹191 Mn (+21.4% YoY) with margins at 23.2%.
Outlook
Targeting ~₹100 Mn EBITDA from Aequitas by Year 2; focuses on sustaining profitable growth through hospital channel expansion.
Risks
Potential macro-economic shifts, regulatory trends, and competitive pressures within the pharmaceutical industry.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 14.2% in Q4 (= BEAT)
- Guided 1.5x IPM growth → delivered 1.35x (14.2% vs 10.5% IPM) (= BEAT)
- Guided 9-10 new launches/SKUs for FY26 → delivered 9 (6 products + 3 SKUs) (= BEAT)
Partly delivered
- Guided FY26 revenue growth 12-14% → delivered 7% (= MISS)
Investor Presentation filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹216.15
- Market cap
- ₹1,426 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 31.3×Sector 43.7×
- Promoter holding
- 68.81%-0.24% QoQ
- FII holding
- 2.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.
Jagsonpal Pharmaceuticals Results Update
Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.
Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.6 Cr · +0.0% YoY
Jagsonpal Pharmaceuticals Board Meeting Date
Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.
Jagsonpal Pharmaceuticals Other Announcement
Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).
Jagsonpal Pharmaceuticals Acquisition
Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.
- From
- Group Pharmaceuticals Limited